Bilgin, B. Et Al. 2021. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.7 , 2145-2152.

Bilgin, B., ŞENDUR, M. A. N., Yucel, S., Celik, E., Ozyukseler, D. T., Ayhan, M., ... Basoglu, T.(2021). Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.7, 2145-2152.

Bilgin, Burak Et Al. "Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.7, 2145-2152, 2021

Bilgin, Burak Et Al. "Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.7, pp.2145-2152, 2021

Bilgin, B. Et Al. (2021) . "Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.7, pp.2145-2152.

@article{article, author={Burak Bilgin Et Al. }, title={Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2021, pages={2145-2152} }